Flurry of Bullish Inflows Sends United Therapeutics Higher
United Therapeutics Corporation (UTHR) shares up 3,603% since Big Money first bought big in 2004.
Fiscal Year: January - December
United Therapeutics Corporation (UTHR), listed on the NASDAQ, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $489.31 per share, offering investors a clear view of its current market value. United Therapeutics Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 18.55, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. United Therapeutics Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that United Therapeutics Corporation (UTHR) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for United Therapeutics Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for United Therapeutics Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for United Therapeutics Corporation is 18.78, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, United Therapeutics Corporation (UTHR) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether United Therapeutics Corporation (UTHR) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of United Therapeutics Corporation (UTHR) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of United Therapeutics Corporation. To access the full SS Score, consider upgrading your subscription.
United Therapeutics Corporation is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 18.55. Investors should compare these metrics with industry peers to gauge whether United Therapeutics Corporation is outperforming or underperforming within its sector.
United Therapeutics Corporation (UTHR) shares up 3,603% since Big Money first bought big in 2004.
United Therapeutics Corporation ( UTHR) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Harrison Silvers - Manager of Investor Relations James Edgemond ...
United Therapeutics Corporation ( UTHR) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Patrick Poisson - Executive VP of Technical Operations Conference Call...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide a...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its EXPAND study of the UKi...
United Therapeutics Corporation ( UTHR) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Harrison Silvers - Manager of Investor Relations Martine Rothblatt - Founder, Chairman ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quart...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before t...
SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHE...
United Therapeutics Corporation - Special Call Company Participants Harrison Silvers - Manager of Investor Relations Leigh Peterson - Executive Vice President of Product Development & Xenotransplantat...
United Therapeutics Corporation (NASDAQ:UTHR) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT Company Participants Harrison Silvers Martine Rothblatt - Founder, Chair...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairpe...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commer...
United Therapeutics Corporation (NASDAQ:UTHR) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants James Edgemond - CFO & Treasurer Harrison Silv...
United Therapeutics delivered strong phase 3 TETON-2 results for nebulized Tyvaso in IPF, meeting the primary endpoint and unlocking major catalyst potential. Tyvaso's efficacy in improving FVC in IPF...
United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic...
United Therapeutics Corporation UTHR released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).
Shares of United Therapeutics jumped nearly 40% on Tuesday's opening trade after the company reported its inhaled lung therapy Tyvaso met the main goal in a late-stage study for idiopathic pulmonary f...
Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial O...
United Therapeutics Corporation remains a Buy as it robustly defends its PAH franchise, counters competitive threats, and posts strong Q2 results with double-digit growth. Upcoming TETON-2 data for Ty...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that it will enter today into two Accelerate...
Earnings Summary on United Therapeutics
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 1.20B | 10.70% | Est @10.7% |
| 2026 | 1.31B | 9.66% | Analyst x5 |
| 2027 | 1.39B | 6.30% | Analyst x5 |
| 2028 | 1.63B | 16.80% | Analyst x5 |
| 2029 | 2.03B | 24.40% | Analyst x5 |
| 2030 | 2.20B | 8.58% | Est @8.6% |
| 2031 | 2.35B | 6.74% | Est @6.7% |
| 2032 | 2.48B | 5.45% | Est @5.5% |
| 2033 | 2.59B | 4.55% | Est @4.5% |
| 2034 | 2.68B | 3.65% | Est @3.7% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 747.60M | 1.00 | 747.60M |
| 2024A | 1.08B | 1.00 | 1.08B |
| 2025E | 1.20B | 1.08 | 1.10B |
| 2026E | 1.31B | 1.18 | 1.11B |
| 2027E | 1.39B | 1.28 | 1.09B |
| 2028E | 1.63B | 1.38 | 1.18B |
| 2029E | 2.03B | 1.50 | 1.35B |
| 2030E | 2.20B | 1.63 | 1.35B |
| 2031E | 2.35B | 1.77 | 1.33B |
| 2032E | 2.48B | 1.92 | 1.29B |
| 2033E | 2.59B | 2.08 | 1.24B |
| 2034E | 2.68B | 2.26 | 1.19B |
| Terminal | 46.01B | 2.26 | 20.39B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.